<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02652637</url>
  </required_header>
  <id_info>
    <org_study_id>HYKS-MOBILE</org_study_id>
    <nct_id>NCT02652637</nct_id>
  </id_info>
  <brief_title>MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.</brief_title>
  <official_title>MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <brief_summary>
    <textblock>
      Enchanced recovery after surgery (ERAS) protocols aim to provide safer and quicker recovery
      postoperatively. One of the elements in ERAS protocols is that bowel is not prepared before
      colorectal surgery. However, several recent retrospective register studies have suggested
      that mechanical bowel preparation combined to oral antibiotics before colectomy reduces
      complications compared to no preparation at all. This trial compares these two strategies to
      find out whether complications can indeed be reduced by mechanically preparing the bowel with
      oral antibiotics.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical site infection (CDC criteria)</measure>
    <time_frame>30 days from operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comprehensive Complication Index</measure>
    <time_frame>30 days from operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anastomotic dehiscence</measure>
    <time_frame>30 days from operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperations</measure>
    <time_frame>30 days from operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>30 days from operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>During hospital stay, anticipated 2-30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30- and 90-days from operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects of antibiotics (diarrhea, clostridium)</measure>
    <time_frame>30 days from operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients receiving adjuvant therapy divided by patients needing adjuvant therapy</measure>
    <time_frame>6 months from operation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>5-year overall survival</measure>
    <time_frame>5 years from operation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>5-year disease specific survival</measure>
    <time_frame>5 years from operation</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>5-year recurrence free survival</measure>
    <time_frame>5 years from operation</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">417</enrollment>
  <condition>Colorectal Surgery</condition>
  <arm_group>
    <arm_group_label>Mechanical and oral antibiotic bowel preparation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical bowel preparation using PEG, neomycin 2g p.o. (single-dose), and metronidazole 2g p.o. (single dose) are given the day before surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No bowel preparation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No mechanical bowel preparation or oral antibiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neomycin, metronidazole, polyethylene glycol (PEG)</intervention_name>
    <arm_group_label>Mechanical and oral antibiotic bowel preparation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing colon resection

        Exclusion Criteria:

          -  Emergency surgery needed

          -  Bowel obstruction

          -  Colonoscopy scheduled to be undertaken peroperatively

          -  Other reason indicating mechanical preparation or contradicting it

          -  Allergy to used drugs (PEG, neomycin, metronidazole)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Finland Central Hospital</name>
      <address>
        <city>Jyvaskyla</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinäjoki Central Hospital</name>
      <address>
        <city>Seinäjoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2016</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville Sallinen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Neomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

